Cypress Capital Management (Wyoming)’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-667
| Closed | -$5.65K | – | 167 |
|
|
2024
Q1 | $5.65K | Hold |
667
| – | – | 0.01% | 122 |
|
|
2023
Q4 | $2.73K | Buy |
667
+467
| +234% | +$1.91K | ﹤0.01% | 134 |
|
|
2023
Q3 | $600 | Buy |
200
+133
| +199% | +$399 | ﹤0.01% | 162 |
|
|
2023
Q2 | $2.06K | Buy |
+67
| New | +$2.06K | ﹤0.01% | 144 |
|
|
2022
Q4 | – | Sell |
-1,067
| Closed | -$71K | – | 164 |
|
|
2022
Q3 | $71K | Buy |
1,067
+1,000
| +1,493% | +$66.5K | 0.1% | 59 |
|
|
2022
Q2 | $3K | Buy |
+67
| New | +$3K | ﹤0.01% | 141 |
|
|
2022
Q1 | – | Sell |
-100
| Closed | -$6K | – | 176 |
|
|
2021
Q4 | $6K | Buy |
+100
| New | +$6K | 0.01% | 215 |
|
|
2021
Q3 | – | Sell |
-67
| Closed | -$4K | – | 244 |
|
|
2021
Q2 | $4K | Hold |
67
| – | – | ﹤0.01% | 262 |
|
|
2021
Q1 | $4K | Hold |
67
| – | – | ﹤0.01% | 242 |
|
|
2020
Q4 | $5K | Buy |
67
+34
| +103% | +$2.54K | ﹤0.01% | 201 |
|
|
2020
Q3 | $9K | Hold |
33
| – | – | 0.01% | 157 |
|
|
2020
Q2 | $6K | Buy |
+33
| New | +$6K | 0.01% | 168 |
|